ROVI — Laboratorios Farmaceuticos Rovi SA Cashflow Statement
0.000.00%
Last trade - 00:00
- €4.40bn
- €4.45bn
- €829.51m
- 90
- 12
- 97
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 41.9 | 72.6 | 183 | 258 | 220 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -0.447 | 1.77 | -1.6 | 0.137 | 1.96 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -68.7 | -47.1 | -53 | -43.4 | -133 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -9.04 | 46.9 | 149 | 238 | 113 |
Capital Expenditures | -40.5 | -39.7 | -40.9 | -51.4 | -55.2 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.053 | 0.067 | 0.101 | -5.77 | 3.16 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -40.5 | -39.6 | -40.8 | -57.2 | -52 |
Financing Cash Flow Items | -0.093 | -0.299 | -0.288 | 1.08 | 2.39 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 21.4 | -21.5 | -62.7 | -155 | -161 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -28.1 | -14.3 | 45.9 | 25.9 | -99.6 |